GSK1363089

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Solid Tumours

Phase 1

A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors

CompletedNCT00742261

GlaxoSmithKlineSolid Tumours

Start: 2008-08-11End: 2009-06-24Updated: 2017-07-07

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

CompletedNCT00742131

GlaxoSmithKlineSolid Tumours

Start: 2005-03-17End: 2011-08-29Updated: 2017-07-31